CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:30 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 a.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.
CRISPR Therapeutics (NASDAQ:CRSP), azienda biofarmaceutica specializzata in terapie a base di geni, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
La società terrà una presentazione al H.C. Wainwright 27th Annual Global Investment Conference l'8 settembre alle 16:30 ET e al Morgan Stanley 23rd Annual Global Healthcare Conference il 9 settembre alle 8:30 ET. I webcast in diretta saranno disponibili sul sito web della società, con le registrazioni fruibili per 14 giorni dopo le presentazioni.
CRISPR Therapeutics (NASDAQ:CRSP), una empresa biofarmacéutica especializada en terapias basadas en genes, ha anunciado su participación en dos importantes conferencias para inversores en septiembre de 2025.
La compañía presentará en el H.C. Wainwright 27th Annual Global Investment Conference el 8 de septiembre a las 4:30 p.m. ET y en el Morgan Stanley 23rd Annual Global Healthcare Conference el 9 de septiembre a las 8:30 a.m. ET. Habrá transmisiones en vivo en la web de la empresa, y las repeticiones estarán disponibles durante 14 días tras las presentaciones.
CRISPR Therapeutics (NASDAQ:CRSP)는 유전자 기반 치료제 개발을 전문으로 하는 생명공학 회사로, 2025년 9월 두 곳의 주요 투자자 콘퍼런스에 참여한다고 발표했습니다.
회사는 H.C. Wainwright 27th Annual Global Investment Conference에서 9월 8일 동부시간 오후 4시 30분에, Morgan Stanley 23rd Annual Global Healthcare Conference에서 9월 9일 동부시간 오전 8시 30분에 발표를 진행합니다. 실시간 웹캐스트는 회사 웹사이트에서 제공되며, 발표 후 14일간 다시보기가 가능합니다.
CRISPR Therapeutics (NASDAQ:CRSP), une société biopharmaceutique spécialisée dans les médicaments à base de gènes, a annoncé sa participation à deux grandes conférences investisseurs en septembre 2025.
La société présentera au H.C. Wainwright 27th Annual Global Investment Conference le 8 septembre à 16h30 ET et au Morgan Stanley 23rd Annual Global Healthcare Conference le 9 septembre à 8h30 ET. Des webcasts en direct seront disponibles sur le site de la société, avec des rediffusions accessibles pendant 14 jours après les présentations.
CRISPR Therapeutics (NASDAQ:CRSP), ein biopharmazeutisches Unternehmen, das sich auf gentherapiebasierte Medikamente spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am H.C. Wainwright 27th Annual Global Investment Conference am 8. September um 16:30 Uhr ET und am Morgan Stanley 23rd Annual Global Healthcare Conference am 9. September um 8:30 Uhr ET präsentieren. Live-Webcasts sind auf der Firmenwebseite verfügbar; Aufzeichnungen können 14 Tage nach den Präsentationen abgerufen werden.
- None.
- None.
ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
H.C. Wainwright 27th Annual Global Investment Conference
Date: Monday, September 8, 2025
Time: 4:30 p.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Tuesday, September 9, 2025
Time: 8:30 a.m. ET
A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Morgan Stanley Healthcare Conference 2025?
How can I watch CRISPR Therapeutics' (CRSP) conference presentations in September 2025?
What investor conferences is CRISPR Therapeutics (CRSP) attending in September 2025?
What time is CRISPR Therapeutics' (CRSP) presentation at the H.C. Wainwright Conference?
